Picture of Zynerba Pharmaceuticals logo

ZYNE — Zynerba Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-22.16%
3m-37.62%
6m-48.16%
1yr-43.27%
Volume Change (%)
10d/3m-43.37%
Price vs... (%)
52w High-73.67%
50d MA-26.65%
200d MA-43.53%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-48.2%
Return on Equity-52.45%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Zynerba Pharmaceuticals EPS forecast chart

Profile Summary

Zynerba Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company. The Company is focused on the development of pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and a heterogeneous group of rare epilepsies known as developmental and epileptic encephalopathies (DEE). Its lead product candidate, Zygel (ZYN002 CBD Gel) is a cannabidiol (CBD) gel for FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare epilepsies known as DEE. Its clinical program for Zygel includes clinical trials evaluating Zygel in the treatment of behavioral symptoms of FXS, ASD and 22q and the reduction of seizures and the treatment of associated symptoms in patients with DEE syndromes.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
January 31st, 2007
Public Since
August 5th, 2015
No. of Shareholders
49
No. of Employees
26
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
41,217,537

ZYNE Share Price Performance

Similar to ZYNE

Picture of 4d Pharma logo

4d Pharma

us flag iconNASDAQ Global Market

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Acceleron Pharma logo

Acceleron Pharma

us flag iconNASDAQ Global Market

Picture of AcelRx Pharmaceuticals logo

AcelRx Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

FAQ

Or unlock with your email

Or unlock with your email